Caroline A Browne

PhD

Department of Primary Appointment:
School of Medicine
Pharmacology & Molecular Therapeutics
Location: Uniformed Services University of the Health Sciences, Bethesda, MD
Research Interests:
Stress Neurobiology
Drug development for psychiatric disorders
Office Phone

Education

University College Cork, Cork, Ireland B.Sc. 2006 Neuroscience
University College Cork, Cork, Ireland Ph.D. 2012 Pharmacology
University of Pennsylvania, Philadelphia, PA Postdoc 2016 Neuropharmacology

Biography

Previous Employment
2006-12 Graduate Research, Dept. of Pharmacology & Therapeutics, University College Cork, Cork, Ireland.
2010-12 Senior Research Scientist, GlaxoSmithKline/Alimentary Pharmabiotic Centre, Cork, Ireland
2012-12 Research Scientist/Analyst, Alimentary Health, Kinsale Rd, Cork, Ireland.
2013-15 Post-doctoral Researcher, Behavioral Psychopharmacology, Dept. Psychiatry, University of Pennsylvania, Philadelphia, PA
2016-present Research Assistant Professor, Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, MD

Awards, Honors and Membership in Honorary Societies:
2008 Travel award - ECNP Workshop on Neuropsychopharmacology for Young Scientists in Europe
2009 Travel award - ECNP Workshop on Neuropsychopharmacology for Young Scientists in Europe.
2009 Poster prize - Translational Health Research Conference, University College Cork, Cork, Ireland
2009 Travel bursary – European Behavioural Pharmacology Society Biennial meeting
2011 Best presentation in the Poster Blitz session - Neuroscience Ireland
2014 American College of Neuropsychopharmacology travel awardee 2014
2015 Penn center for innovation (PCI) Fellowship, University of Pennsylvania, Philadelphia, Pennsylvania, USA
2017 Poster award – preclinical research, 12th Annual Amygdala, Stress, PTSD Conference, Uniformed Services University, Bethesda, MD.

Other Experience and Professional Membership
2006 Member, Neuroscience Ireland
2007 – 2012 Member, Cork Neuroscience Society
2009 Member, European Behavioural Pharmacology Society (EBPS)
2009 Local organizing committee, European Behavioural Pharmacology Society Workshop on Behavioural Genetics and Neuropsychiatric Disorders
2010 Member, Federation of European Neuroscience Societies (FENS)
2014 Member, Society for Neuroscience
2014 Nanosymposium chair of Mood Disorders: Novel Therapeutic Mechanisms at Society for Neuroscience annual conference.
2014 – 2015 Poster Judge at the BGSA, Biomedical, Health and Natural Sciences Research Day, University of Pennsylvania.
2012 – Present Reviewer for Neuropharmacology, Physiology and Behavior, Psychopharmacology, Journal of Neurochemistry, Pharmacology Biochemistry and Behavior, Neurobiology of stress, Neuropsychopharmacology, Biological Psychiatry, British Journal of Pharmacology and Journal of Affective Disorders.
2016 – Present Established and organized monthly meetings of the Neuropharmacology Drug Club at the Uniformed Services University. This is an interdepartmental effort where, PIs or members of their research group present data ultimately with an aim of establishing research collaborations and improving funding proposals.
2016 – Present Advisory committee member for the rat behavioral core (RBC), Uniformed Services University.
2016 – Present Advisory committee member for the mouse preclinical core, Uniformed Services University.
2016 – Present Poster Judge at high school students summer research program USURTP, Uniformed Services University.
2019 – Present Guest associate editor for Frontiers in Synaptic Neuroscience
2019 – Present Current Chair of the Recruitment Committee for the Uniformed Services University Neuroscience Program
2020 – Present Topic editor for Frontiers in Synaptic Neuroscience
2020 – Present Member, The American Society for Pharmacology and Experimental Therapeutics (ASPET)

Peer-reviewed Publications
1. Browne CA, Clarke G, Dinan TG, Cryan JF. Alterations in TPH activity following Restraint Stress in 2 mouse strains with different functional polymorphisms of the TPH gene. Neuropharmacology. 2011. 60(4): 683-691. PMID: 21130784
2. Browne CA, Clarke G, Dinan TG, Cryan JF. An effective dietary method for chronic tryptophan depletion in two mouse strains illuminates a Role for 5-HT in nesting behaviour. Neuropharmacology 2012. 62(5-6): 1903-1915. PMID: 22212181
3. Browne CA, O'Brien FE, Connor TJ, Dinan TG, Cryan JF. Differential lipopolysaccharide-induced immune alterations in the hippocampus of two mouse strains: Effects of stress. Neuroscience. 2012. Dec 6; 225:237-48. PMID: 22917616
4. Browne CA, Clarke G, Hanke J, Dinan TG, Schwegler H, Yilmazer-Hanke DM, Cryan JF. Alterations in prefrontal cortical serotonin and antidepressant-like behavior in a novel C3H/HeJxDBA/2J recombinant inbred mouse strain. Behavioral Brain Research. 2013 Jan 1; 236(1): 283-8. PMID: 22960457
5. ***Browne CA and Lucki I. Mechanisms mediating the antidepressant-like effects of Ketamine: Screening for Fast-Acting Novel Antidepressants. Frontiers in Pharmacology. 2013 Dec 27; 4:161 PMID: 24409146
6. Arnold SE, Lucki I. Brookshire BR, Carlson GC, Browne CA, Kazi H, Bang S, Choi BR, Chen Y, McMullen MF, Kim SF. High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice. Neurobiology of Disease. 2014 Mar 29; 67C: 79-87. PMID: 24686304
7. Browne CA, Hanke J, Rose C, Walsh I, Foley T, Clarke G, Schwegler H, Cryan JF, Yilmazer-Hanke DM, Effect of acute swim stress on plasma corticosterone and brain monoamine levels in bidirectionally selected DxH recombinant inbred mouse strains differing in fear recall and extinction. Stress. 2014. 17(6): p. 471-83. PMID: 25117886
8. Browne CA, van Nest DS, Lucki I. Antidepressant-like effects of buprenorphine in rats are strain dependent. Behavioral Brain Research. 2015. 278C: p. 385-392. PMID: 25453747
9. Falcon E^, Browne CA^, Leon R, Fleites V, Sweeney R, Kirby LG, Lucki I. Antidepressant-like effects of buprenorphine are mediated by kappa opioid receptors. Neuropsychopharmacology. 2016 Aug;41(9):2344-51 PMID: 26979295
10. Robinson SA, Erickson RL, Browne CA, Lucki I. A role for the mu opioid receptor in the antidepressant effects of buprenorphine. Behavioral Brain Research. 2016 Nov 3;319:96-103. PMID: 27818236
11. *Browne CA, Erickson RL, Blendy JA, Lucki I Genetic variation in the behavioral effects of buprenorphine in female mice derived from a murine model of the OPRM1 A118G polymorphism. Neuropharmacology. 2017 117:401-407 PMID: 28089708
12. Erickson RL, Browne CA, Lucki I Hair corticosterone measurement in mouse models of type 1 and type 2 diabetes mellitus. Physiology & Behavior, 2017, pii: S0031-9384(16)30843-5. PMID: 28188737
13. Browne CA, Falcon E, Robinson SA, Berton O, Lucki I. Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine. International Journal of Neuropsychopharmacology, 2018, Feb 1;21(2):164-174. PMID: 29020387
14. **Authement ME, Langlois LD, Shepard RD, Browne CA, Lucki I, Kassis H, Nugent FS. A role for corticotropin-releasing factor signaling in the lateral habenula and its modulation by early-life stress. Science Signaling, 2018 Mar 6;11(520). pii: eaan6480. PMID: 29511121
15. *Jacobson ML, Wulf HA, Browne CA, Lucki I. Kappa opioid receptors cognitive and motivational deficits in Invited review Progress in Brain Research, 2018; 239:1-48. PMID: 30314565
16. Shepard RD, Langlois LD, Aylar Berenji, Lucki I, Browne CA, Nugent FS. Ketamine reverses behavioral deficits and neurophysiological alterations in the lateral habenula of maternally deprived rats. Invited research article Frontiers in Synaptic Neuroscience. 2018 Oct 30;10:39.PMID: 30425634
17. *#Browne CA, Hammack R, Lucki I. Aberrant GABA tone in the lateral habenula; aversion and depression. Invited review Frontiers in Synaptic Neuroscience., 07 December 2018. PMID: 30581384
18. Browne CA, Lucki I. Targeting opioid dysregulation in depression for the development of novel therapeutics. Pharmacology & Therapeutics. 2019 Apr 30. pii: S0163-7258(19)30072-5. PMID: 31051197
19. Browne CA, Jacobson ML, Lucki I. Novel targets to treat depression: opioid-based therapeutics. Harvard Review of Psychiatry. 2020 Jan/Feb;28(1):40-59. PMID: 31913981
20. Jacobson ML, Browne CA, Lucki I. Kappa opioid receptor antagonists as potential therapeutics for stress-related disorders. Annual Reviews of Pharmacology & Toxicology. 2020 Jan 6;60:615-636. PMID: 31914893
21. *Browne CA, Smith T, Lucki I. Behavioral effects of the kappa opioid receptor partial agonist nalmefene in tests relevant to depression. European Journal of Pharmacology. 2020 Apr 5;872:172948. PMID: 31991139
22. Jacobson ML, Wulf HA, Tsuda MC, Browne CA, Lucki I. Sex differences in the modulation of mouse nest building behavior by kappa opioid receptor signaling. Neuropharmacology. 2020 Jul 26;108254. PMID: 32726598
23. *Jacobson ML, Wulf HA, Browne CA, Lucki I. The Kappa Opioid Receptor Antagonist Aticaprant Reverses Behavioral Effects from Unpredictable Chronic Mild Stress in the Mouse. Psychopharmacology. 2020 Dec;237(12):3715-3728. PMID: 32894343
24. *Browne CA, Wulf H, Lucki I. Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder. Handb Exp Pharmacol. 2021 Feb 14. PMID: 33580854
25. *Kostelnik C., Lucki I., Choi K.H., Browne CA. Translational relevance of fear conditioning in rodent models of mild traumatic brain injury. Neuroscience & Biobehavioral Reviews Volume 127, August 2021, Pages 365-376. Available online 4 May 2021.

* Corresponding author
** Article featured on journal cover
*** Article has over 47,800 views, 40,000 downloads and 180 citations
^ Co first author
# Article has over 11800 views, 9600 downloads and 19 citations

Bibliography

Kostelnik C., Lucki I., Choi K.H., Browne CA. Translational relevance of fear conditioning in rodent models of mild traumatic brain injury. Neuroscience & Biobehavioral Reviews Volume 127, August 2021, Pages 365-376. Available online 4 May 2021.

Browne CA, Wulf H, Lucki I. Kappa Opioid Receptors in the Pathology and Treatment of Major Depressive Disorder. Handb Exp Pharmacol. 2021 Feb 14. PMID: 33580854

Browne CA, Hammack R, Lucki I. Aberrant GABA tone in the lateral habenula; aversion and depression. Invited review Frontiers in Synaptic Neuroscience., 07 December 2018. PMID: 30581384

Browne CA, Lucki I. Targeting opioid dysregulation in depression for the development of novel therapeutics. Pharmacology & Therapeutics. 2019 Apr 30. pii: S0163-7258(19)30072-5. PMID: 31051197

Jacobson ML, Browne CA, Lucki I. Kappa opioid receptor antagonists as potential therapeutics for stress-related disorders. Annual Reviews of Pharmacology & Toxicology. 2020 Jan 6;60:615-636. PMID: 31914893

Browne CA and Lucki I. Mechanisms mediating the antidepressant-like effects of Ketamine: Screening for Fast-Acting Novel Antidepressants. Frontiers in Pharmacology. 2013 Dec 27; 4:161 PMID: 24409146